Navigation Links
Regulus Provides Update on 'Road to the Clinic' Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
Date:5/14/2013

f $7.2 million for the quarter ended March 31, 2013, compared to a net loss of $2.2 million for the quarter ended March 31, 2012.  The quarter ended March 31, 2013, included non-cash charges of $1.8 million from the change in value of the amended and restated convertible promissory note originally issued to GlaxoSmithKline in 2010, which was attributable to increases in value of the underlying common stock of the Company since December 31, 2012.  Basic and diluted net loss per share was $0.20 for the quarter ended March 31, 2013, compared to net loss per share of $13.06 for the quarter ended March 31, 2012. The comparison of net loss per share for the periods presented is impacted by the initial public offering and concurrent common stock issuances in October 2012.

Regulus recognized revenue of $3.2 million for the quarter ended March 31, 2013, compared to $3.3 million for the quarter ended March 31, 2012.  Revenue during these periods consisted primarily of amortization of up-front payments received from our strategic alliances and collaborations, which is recognized over the estimated period of performance.

Research and development expenses were $6.9 million for the quarter ended March 31, 2013, compared to $4.6 million for the quarter ended March 31, 2012.  The increase is attributable to an expansion of our research and development team, expertise and capabilities, in addition to increasing pre-clinical study activities in the first quarter of 2013, compared to the same period in 2012.

General and administrative expenses were $1.9 million for the quarter ended March 31, 2013, compared to $0.9 million for the quarter ended March 31, 2012.  The increase is attributable to costs associated with increases related to additional personnel required to support the growth of the business, in addition to an increase in overall operating costs associated with being an SEC registrant in the first quarter of 2013, compared to the
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
2. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
3. Regulus to Present at Future Leaders in the Biotech Industry Conference
4. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
5. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
6. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
7. Regulus to Present at Two Upcoming Investor Conferences
8. Regulus Appoints Mark G. Foletta to its Board of Directors
9. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
10. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
11. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Cardinal Innovations Healthcare Solutions , ... high-touch service delivery, is featuring its highly successful ... National Council for Behavioral Health,s annual National Conference ... 2015, at the Gaylord Palms Resort and Convention ... attracts participants from mental health and addiction treatment ...
(Date:4/20/2015)... 20, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... and drug-delivery therapies, today shared highlights of new ... Cancer Research (AACR) annual meeting. Halozyme also announced ... Phase 2 study in pancreatic cancer, Study 202, ... American Society of Clinical Oncology (ASCO). ...
(Date:4/20/2015)... , April 20, 2015  Published results ... trends in the ability of Neuraltus Pharmaceuticals ... of amyotrophic lateral sclerosis (ALS, also known as ... treatment period. While NP001,s slowing of decline in ... was not statistically significant, clinically meaningful slowing of ...
Breaking Medicine Technology:Cardinal Innovations Highlights its Managed Care Model During National Council for Behavioral Health's Annual Conference 2Cardinal Innovations Highlights its Managed Care Model During National Council for Behavioral Health's Annual Conference 3Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 2Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 3Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 4Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 5Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 2Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 3Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 4Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 5
... Pursuant to the filing of a Form 13D with the ... global leader in protection solutions, today announced it has made ... acquired 9.66% of the issued and outstanding shares of common ... manufactures and sells a comprehensive line of safety garments and ...
... SCOLR Pharma, Inc. (OTCQB: SCLR) today announced that ... its extended-release nutritional products based on the Company,s proprietary ... first significant direct retail sales of its nutritional products. ... CEO, said, "Shipment of these initial orders marks an ...
Cached Medicine Technology:SCOLR Pharma, Inc. Announces Initial Shipments of its Nutritional Products 2
(Date:4/20/2015)... Mutare Health, a Strategic Business ... Lawrence Kosinski, MD, MBA, AGAF, to serve as ... a unique combination of medical experience, technical expertise, ... Health team as it continues to develop ... of care in the healthcare environment. He is ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Goodreads is ... Health Insurance: Why It’s Good for You and Your ... Paul Zane Pilzer and Rick Lindquist have released ... Insurance: Why It’s Good for You and Your Company. ... employer health insurance woes - employer-funded individual health insurance. ...
(Date:4/20/2015)... April 20, 2015 Advance Home Care ... personal matter that many customers would prefer not to share ... March 30th a discreet delivery method allowing customers to order ... at their home without fear of a neighbor or passerby ... method is available now on all orders and no minimum ...
(Date:4/20/2015)... Florida Hospital at Connerton Long Term ... from Select Medical, during the annual ceremony hosted at ... Chief Operating Officer, Debi Martoccio, received the Leadership Award ... of six recipients out of 113 hospitals nationwide. The ... for the contributions to the community as well as ...
(Date:4/20/2015)... 1% for the Planet , one of the ... Williams, the network’s Director of Partnerships, will step into the ... been part of 1% for the Planet since early 2014, ... Northern Forest Canoe Trail, a 1% for the Planet nonprofit ... of and advocacy for the outdoors, a commitment which is ...
Breaking Medicine News(10 mins):Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 3Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 3Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 3Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 2Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 3Health News:1% for the Planet Announces New CEO 2Health News:1% for the Planet Announces New CEO 3
... , WEDNESDAY, Jan. 5 (HealthDay News) -- Women with ... to have a gene thought to be connected to the ... help researchers gain more insight into the development of MS, ... particularly among women. Although no one knows what causes MS, ...
... Lou Gehrig,s disease, or amyotrophic lateral sclerosis (ALS), ... clumps in brain and spinal-cord cells that include an ... building block of the lesions formed by these clumps. ... Journal of Clinical Investigation , a team led by ...
... are reporting development of a less expensive, more eco-friendly method ... may be a more healthful form of water. Their report ... Research . Changgong Meng and Feng Huang note ... mixture of H2O and tiny amounts of D2O about ...
... of researchers at the Columbia University College of Dental ... key role in vascular pathogenesis, specifically atherosclerosis, or what ... the number one cause of death in the ... in cardiovascular diseases has been challenging because researchers have ...
... maximum temperature of children,s bath water can significantly reduce ... the risk of scalding, according to researchers at The ... partnership with Glasgow Housing Association, found that families with ... and cold water pipes in their bathroom had bath ...
... New Rochelle, NY, January 5, 2011A new, simplified method ... of shuttling genes into host cells will help advance ... into large animal studies and human clinical trials. The ... an article published Instant Online ahead of publication in ...
Cached Medicine News:Health News:Study Sheds Light on Genetic Risk of MS 2Health News:Malfunctioning gene associated with Lou Gehrig's disease leads to nerve-cell death in mice 2Health News:Bacteria eyed for possible role in atherosclerosis 2Health News:Bacteria eyed for possible role in atherosclerosis 3Health News:Thermostatic mixer valves could significantly reduce the risk of scalding in children, study finds 2Health News:Thermostatic mixer valves could significantly reduce the risk of scalding in children, study finds 3Health News:Faster, scalable method for producing AAV-based gene transfer vectors 2
Bio-Rad's Liquichek™ D-dimer Control provides the laboratory with a liquid, trilevel, human plasma based control for the monitoring of D-dimer testing on most automated coagulation, chemistry a...
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek Diabetes Control is a human whole blood based product used to monitor hemoglobin fractions associated with diabetes, including Hemoglobins A1, A1C, F and Total Glycated Hemoglobin....
... Liquichek Qualitative Urine Toxicology Control is a ... rapid urine drug screen panels, including Point ... test kits like Bio-Rad TOX/See, Biosite Triage ... qualitative results (+/) for popular kits and ...
Medicine Products: